The therapeutic potential of TRAIL receptor signalling in cancer cells

Clinical and Translational Oncology

Volumn 13, Issue 12, 2011, Pages 839-847

  Yerbes, Rosario ^a   Palacios, Carmen ^a   López Rivas, Abelardo ^a  

^a CSIC   (Spain)

Author keywords

Apoptosis; Cancer; Clinical trials; Therapy; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; APOMAB; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CASPASE 8; CISPLATIN; CONATUMUMAB; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DOXORUBICIN; DULANERMIN; FLICE INHIBITORY PROTEIN; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GANITUMAB; GEMCITABINE; IRINOTECAN; LEXATUMUMAB; MAPATUMUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RITUXIMAB; SORAFENIB; TIGATUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; VORINOSTAT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CELL DEATH; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOGENE; OVARY CANCER; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOLID TUMOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MICE; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION;

EID: 84856057025     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0744-4     Document Type: Article

References (105)

1. Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239-257
2. Meier P, Finch A, Evan G (2000) Apoptosis in development. Nature 407:796-801
3. Green DR (2003) Overview: apoptotic signaling pathways in the immune system. Immunol Rev 193:5-9 (Pubitemid 36688034)
4. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
5. Raff MC (1992) Social controls on cell survival and cell death. Nature 356:397-400
6. Danial NN, Korsmeyer SJ (2004) Cell death: critical control points. Cell 116:205-219 (Pubitemid 38167313)
7. Kroemer G, Reed JC (2000) Mitochondrial control of cell death. Nat Med 6:513-519 (Pubitemid 30305900)
8. Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487-501 (Pubitemid 32201945)
9. Degterev A, Boyce M, Yuan J (2003) A decade of caspases. Oncogene 22:8543-8567 (Pubitemid 38028527)
10. Nagata S (1997) Apoptosis by death factor. Cell 88:355-365 (Pubitemid 27131377)
11. O'Reilly L, Tai L, Lee L et al (2009) Membranebound Fas ligand only is essential for Fas-induced apoptosis. Nature 461:659-663
12. Bodmer JL, Schneider P, Tschopp J (2002) The molecular architecture of the TNF superfamily. Trends Biochem Sci 27:19-26 (Pubitemid 34131621)
13. Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M (2009) APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457:981-989
14. Wu GS, Burns TF, Zhan Y et al (1999) Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res 59:2770-2775 (Pubitemid 29283105)
15. Wilson NS, Dixit V, Ashkenazi A (2009) Death receptor signal transducers: nodes of coordination in immune signaling networks. Nature Immunol 10:348-355
16. Wiley SR, Schooley K, Smolak PJ et al (1995) Identifi cation and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682 (Pubitemid 26091143)
17. Pitti RM, Marsters SA, Ruppert S et al (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687-12690 (Pubitemid 26175834)
18. Ashkenazi A, Pai RC, Fong S et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162
19. Walczak H, Miller RE, Ariail K et al (1999) Tumoricidal activity of tumor necrosis factorrelated apoptosis-inducing ligand in vivo. Nat Med 5:157-163 (Pubitemid 29068521)
20. Duiker EW, Mom CH, de Jong S et al (2006) The clinical trial of TRAIL. Eur J Cancer 42:2233-2240
21. Pan G, O'Rourke K, Chinnaiyan AM et al (1997) The receptor for the cytotoxic ligand TRAIL. Science 276:111-113 (Pubitemid 27161256)
22. Schneider P, Bodmer JL, Thome M et al (1997) Characterization of two receptors for TRAIL. FEBS Lett 416:329-334 (Pubitemid 27475391)
23. MacFarlane M, Ahmad M, Srinivasula SM et al (1997) Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 272:25417-25420 (Pubitemid 27438841)
24. Sheridan JP, Marsters SA, Pitti RM et al (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-821 (Pubitemid 27366733)
25. Walczak H, Degli-Esposti MA, Johnson RS et al (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 16:5386-5397 (Pubitemid 27380146)
26. Degli-Esposti MA, Smolak PJ, Walczak H et al (1997) Cloning and characterization of TRAILR3, a novel member of the emerging TRAIL receptor family. J Exp Med 186:1165-1170 (Pubitemid 27441160)
27. Emery JG, McDonnell P, Burke MB et al (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363-14367 (Pubitemid 28319153)
28. Chan FK, Chun HJ, Zheng L et al (2000) A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288:2351-2354 (Pubitemid 30448156)
29. Wang TT, Jeng J (2000) Coordinated regulation of two TRAIL-R2/KILLER/DR5 Mrna isoforms by DNA damaging agents, serum and 17beta-estradiol in human breast cancer cells. Breast Cancer Res Treat 61:87-96 (Pubitemid 30440553)
30. Merino D, Lalaoui N, Morizot A et al (2006) Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 26:7046-7055 (Pubitemid 44477684)
31. Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176 (Pubitemid 28180851)
32. Cretney E, Takeda K, Yagita H et al (2002) Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing liganddefi cient mice. J Immunol 168:1356-1361 (Pubitemid 34094506)
33. Ichikawa K, Liu W, Zhao L et al (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7:954-960 (Pubitemid 32756434)
34. Rossin A, Derouet M, Abdel-Sater F, Hueber AO (2009) Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling. Biochem J 419:185-192, 2 p following 192
35. Tang Z, Bauer JA, Morrison B, Lindner DJ (2006) Nitrosylcobalamin promotes cell death via S nitrosylation of Apo2L/TRAIL receptor DR4. Mol Cell Biol 26:5588-5594 (Pubitemid 44134317)
36. Wagner KW, Punnoose EA, Januario T et al (2007) Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 13:1070-1077 (Pubitemid 47517508)
37. Diehl GE, Yue HH, Hsieh K et al (2004) TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21:877-889 (Pubitemid 39626676)
38. Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA et al (2003) Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/-mice. Nat Immunol 4:255-260 (Pubitemid 36322135)
39. Grosse-Wilde A, Voloshanenko O, Bailey SL et al (2008) TRAIL-R defi ciency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 118:100-110
40. Takeda K, Hayakawa Y, Smyth MJ et al (2001) Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7:94-100 (Pubitemid 32095647)
41. Sprick MR, Weigand MA, Rieser E et al (2000) FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12:599-609
42. Gonzalvez F, Ashkenazi A (2010) New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 29:4752-4765
43. Yamada H, Tada-Oikawa S, Uchida A, Kawanishi S (1999) TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells. Biochem Biophys Res Commun 265:130-133
44. LeBlanc H, Lawrence D, Varfolomeev E et al (2002) Tumor-cell resistance to death receptorinduced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8:274-281 (Pubitemid 34250106)
45. Luo X, Budihardjo I, Zou H et al (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94:481-490 (Pubitemid 28391864)
46. Irmler M, Thome M, Hahne M et al (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388:190-195 (Pubitemid 27297457)
47. MacFarlane M, Harper N, Snowden RT et al (2002) Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21:6809-6818 (Pubitemid 35221923)
48. Djerbi M, Darreh-Shori T, Zhivotovsky B, Grandien A (2001) Characterization of the human FLICE-inhibitory protein locus and comparison of the anti-apoptotic activity of four different fl ip isoforms. Scan J Immunol 54:180-189 (Pubitemid 32592344)
49. Golks A, Brenner D, Fritsch C et al (2005) c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem 280:14507-14513 (Pubitemid 40562792)
50. Micheau O, Thome M, Schneider P et al (2002) The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 277:45162-45171 (Pubitemid 36159119)
51. Yip KW, Reed JC (2008) Bcl-2 family proteins and cancer. Oncogene 27:6398-6406
52. Xiao C, Yang BF, Asadi N et al (2002) Tumor necrosis factor-related apoptosis-inducing ligandinduced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 277:25020-25025 (Pubitemid 34951805)
53. Palacios C, Yerbes R, Lopez-Rivas A (2006) Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res 66:8858-8869 (Pubitemid 44449204)
54. Sharp DA, Lawrence DA, Ashkenazi A (2005) Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 280:19401-19409 (Pubitemid 41379648)
55. Yerbes R, Palacios C, Reginato MJ, Lopez-Rivas A (2011) Cellular FLIP(L) plays a survival role and regulates morphogenesis in breast epithelial cells. Biochim Biophys Acta 1813:168-178
56. Jin Z, Li Y, Pitti R et al (2009) Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 137:721-735
57. Song JH, Tse MC, Bellail A et al (2007) Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res 67:6946-6955 (Pubitemid 47105542)
58. Kohlhaas SL, Craxton A, Sun XM et al (2007) Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J Biol Chem 282:12831-12841 (Pubitemid 47100635)
59. Zhao X, Liu Y, Ma Q et al (2009) Caveolin-1 negatively regulates TRAIL-induced apoptosis in human hepatocarcinoma cells. Biochem Biophys Res Commun 378:21-26
60. Jin Z, El-Deiry WS (2006) Distinct signaling pathways in TRAIL- versus tumor necrosis factorinduced apoptosis. Mol Cell Biol 26:8136-8148 (Pubitemid 44631011)
61. Varfolomeev E, Maecker H, Sharp D et al (2005) Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factorrelated apoptosis-inducing ligand. J Biol Chem 280:40599-40608 (Pubitemid 41780550)
62. Secchiero P, Melloni E, Corallini F et al (2008) Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells 26:2955-2963
63. Ehrhardt H, Fulda S, Schmid I et al (2003) TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22:3842-3852 (Pubitemid 36819657)
64. Ishimura N, Isomoto H, Bronk SF, Gores GJ (2006) Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 290:G129-136
65. Meurette O, Rebillard A, Huc L et al (2007) TRAIL induces receptor-interacting protein 1-dependent and caspase-dependent necrosis-like cell death under acidic extracellular conditions. Cancer Res 67:218-226 (Pubitemid 46142778)
66. Smyth MJ, Cretney E, Takeda K et al (2001) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gammadependent natural killer cell protection from tumor metastasis. J Exp Med 193:661-670 (Pubitemid 32524460)
67. Zerafa N, Westwood JA, Cretney E et al (2005) Cutting edge: TRAIL defi ciency accelerates hematological malignancies. J Immunol 175:5586-5590 (Pubitemid 41508035)
68. Yue HH, Diehl GE, Winoto A (2005) Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ 12:94-97 (Pubitemid 40090033)
69. Bos PD, Zhang XH, Nadal C et al (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459:1005-1009
70. Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8:782-798
71. Lee SH, Shin MS, Kim HS et al (1999) Alterations of the DR5/TRAIL receptor 2 gene in nonsmall cell lung cancers. Cancer Res 59:5683-5686
72. Shin MS, Kim HS, Lee SH et al (2001) Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 61:4942-4946
73. Sanlioglu AD, Korcum AF, Pestereli E et al (2007) TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat Oncol Biol Phys 69:716-723 (Pubitemid 47418395)
74. Lawrence D, Shahrokh Z, Marsters S et al (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7:383-385
75. Ashkenazi A (2008) Directing cancer cells to selfdestruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7:1001-1012
76. Herbst RS, Eckhardt SG, Kurzrock R et al (2010) Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28:2839-2846
77. Takeda K, Yamaguchi N, Akiba H et al (2004) Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 199:437-448 (Pubitemid 38233828)
78. Wilson NS, Yang B, Yang A et al (2011) An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19:101-113
79. Eramo A, Pallini R, Lotti F et al (2005) Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res 65:11469-11477 (Pubitemid 41821704)
80. Koschny R, Ganten TM, Sykora J et al (2007) TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 45:649-658 (Pubitemid 46450616)
81. Nguyen T, Zhang XD, Hersey P (2001) Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin Cancer Res 7:966s-973s (Pubitemid 33600952)
82. Wu GS, Burns TF, McDonald ER 3rd et al (1997) KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17:141-143
83. Wen J, Ramadevi N, Nguyen D et al (2000) Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 96:3900-3906
84. Greco FA, Bonomi P, Crawford J et al (2008) Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61:82-90
85. Holoch PA, Griffi th TS (2009) TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol 625:63-72
86. Yee L, Fanale M, Dimick K et al (2007) A phase 1b safety and pharmacokinetic (PK) study of recombinant human APO2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma. J Clin Oncol 25:8078
87. Soria JC, Smit E, Khayat D et al (2010) Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 28:1527-1533
88. Ling J, Herbst RS, Mendelson DS et al (2006) APO2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. J Clin Oncol 24:3047
89. Pan Y, Xu R, Peach M et al (2007) Application of phamacodynamic assays in a phase 1a trial of APO2L/TRAIL in patients with advanced tumors. J Clin Oncol 25:3535
90. Tolcher AW, Mita M, Meropol NJ et al (2007) Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25:1390-1395 (Pubitemid 46706887)
91. Younes A, Vose J, Zelenetz AD et al (2005) Results of a phase 2 trial of HGS-ETR1 in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL). 47th Annual Meeting of the American Society of Hematology Abstracts 106:489
92. Kanzler S, Trarbach T, Heinemann V et al (2005) Results of a phase 2 trial of HGS-ETR1 in subjects with relapsed or refractory colorectal cancer (CRC). ECCO 13: The European Cancer Conference Abstract #630
93. Wakelee HA, Patnaik A, Sikic BI et al (2010) Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 21:376-381
94. LoRusso P, Hong D, Heath E et al (2007) First-inhuman study of AMG655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. J Clin Oncol 25:3534
95. Camidge DR (2008) Apomab: an agonist monoclonal antibody directed against death receptor 5/TRAIL-receptor 2 for use in the treatment of solid tumors. Exp Opin Biol Ther 8:1167-1176
96. Saleh MN, Percent I, Wood TE et al (2008) A phase 1 study of CS-1008 administered weekly to patients with advanced solid tumors or lymphomas. J Clin Oncol 26:3537
97. Yee L, Burris HA, Kozloff M et al (2009) Phase 1b study of recombinant human APO2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients: preliminary results. J Clin Oncol 27: 4129
98. Mom CH, Verweij J, Oldenhuis CN et al (2009) Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 15:5584-5590
99. Leong S, Cohen RB, Gustafson DL et al (2009) Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol 27:4413-4421
100. Sikic BI, Wakelee HA, von Mehren M et al (2007) A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. J Clin Oncol 25:14006
101. Paz-Ares L, Sánchez Torres JM, Diaz-Padilla I et al (2009) Safety and effi cacy of AMG 655 in combination with paclitaxel and carboplatin (PC) in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 27:19048
102. Blay J-Y, Chawla S, Demetri GD et al (2008) 2 open-label study of AMG 655 in combination with doxorubicin for the first-line treatment of patients with locally advanced or metastatic, unresectable soft tissue sarcoma. CTOS 14th Annual Meeting, London, p 34845
103. Saltz L, Infante J, Schwartzberg L et al (2009) Safety and effi cacy of AMG 655 plus modifi ed FOLFOX6 and bevacizumab for the first-line treatment of patients with metastatic colorectal cancer. J Clin Oncol 27:4079
104. Kindler HL, Garbo L, Stephenson J et al (2009) A phase 1b study to evaluate the safety and effi cacy of AMG 655 in combination with gemcitabine in patients with metastatic pancreatic cancer. J Clin Oncol 27:4501
105. Rougier P, Infante J, Van Laethem J et al (2009) A phase 1b/2 trial of AMG 655 and panitumumab for the treatment of metastatic colorectal cancer: safety results. J Clin Oncol 27:4130